3 Biotech Stocks to Be Thankful for This Year
Anyone who has been holding onto shares of Loxo Oncology Inc. (NASDAQ: LOXO), Nektar Therapeutics (NASDAQ: NKTR), or Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) will have plenty to say when it's their turn to share at the dinner table this Thanksgiving.
Surprisingly positive trial results for experimental cancer therapies helped shares of all three of these biotechs soar in 2017. Here's a closer look at what helped these stocks generate massive returns this year.
Image source: Getty Images.
Source: Fool.com
Nektar Therapeutics Aktie
1,25 €
3,71 %
Die Community sieht Nektar Therapeutics leicht positiv: Mehr Buy- als Sell-Einschätzungen.
Ein prognostiziertes Kursziel von 2 € für Nektar Therapeutics zeigt ein Potenzial von über 50% im Vergleich zum aktuellen Kurs von 1.25 €.
